Rivaroxaban plus aspirin after iliac vein stenting for deep vein thrombosis
Tests rivaroxaban with aspirin after vein stenting in people with leg clots.
Key facts
- Who runs it
- First Affiliated Hospital of Zhejiang University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
- Status
- Recruiting
- People taking part
- 172 people, planned
- Started
- 3 Nov 2021
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Treatments tested
- Rivaroxaban
- Aspirin
- Record updated
- 25 September 2025
Who can take part
The trial is looking for adults with a recent deep vein clot (DVT) and a narrowed iliac vein in the pelvis on the same side. They must have had the clot removed with a catheter and a stent placed in the iliac vein.
- Age
- 18 years and older
- Sex
- All
- Disease stage
- Acute DVT that started no more than 3 weeks ago and reaches the thigh or pelvic veins. The iliac vein on the same side is narrowed by more than 50%. The narrowing comes from vein compression (Cockett syndrome) or clot left after removal.
- Earlier treatment
- Must have had percutaneous mechanic thrombectomy (PMT), a catheter procedure to remove the clot, with or without catheter directed thrombolysis (CDT). Must have had an iliac vein stent placed within 30 days of PMT or CDT. Cannot join if already taking blood thinners or antiplatelet drugs for other diseases before the DVT.
- Main reasons for not taking part
- Long-standing (chronic) DVT, or DVT that started more than 3 weeks ago, or a clot only in the lower leg
- Glomerular filtration rate (kidney function) below 60ml/min
- Varicose veins or poor vein function in the same leg before the DVT
- Heart attack in the past 6 months, or artery blockage, narrowing, aneurysm or tear in the belly or leg arteries
- High bleeding risk, or unable to take antiplatelet drugs or anticoagulants
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- IC1. Subjects who were diagnosed with deep venous thrombus (DVT) with ipsilateral iliac venous stenosis (>50%). The ipsilateral iliac venous stenosis can be caused either by iliac vein compression (i.e. Cockett syndrome) or residue iliac venous thrombus after percutaneous mechanic thrombectomy
- IC2. Subjects who accepted percutaneous mechanic thrombectomy (PMT) to decrease the burden of thrombus, with or without catheter directed thrombolysis (CDT)
- IC3. Subjects who accepted iliac venous stent(s) implantation during the perioperative period of PMT or CDT (≤30 days post PMT or CDT)
Who cannot take part
- EC3. Subject has glomerular filtration rate < 60ml/min. EC4. Subject has ipsilateral varicose vein or suffers from ipsilateral venous insufficiency prior to the DVT. The manifestations of venous insufficiency include skin pigmentation, edema, lipodermatosclerosis and venous ulcer
- EC9. Subject has been taking anticoagulants or antiplatelet drugs for other diseases prior to the DVT
- EC7. Subject has contraindication to antiplatelet drugs or anticoagulants. EC8. Subject has systemic disease(s) that cannot be treated by current medicine
- Subject who has at least one of the below conditions will be considered at high bleeding risk: Primary history of intracerebral haemorrhage or ischemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR <15ml/min/1.73 m2
- EC10. Subject less than 18 years old or rejected to join this study. EC11. Subject has myocardial infarction during the past 6 months. EC12. EC12. Subject who is at high bleeding risk*
- EC1. Subject has chronic DVT or the onset of DVT is longer than 3 weeks, or chronic DVT
- EC2. Subject has isolated distal DVT, which does not affect ipsilateral femoral or iliac vein
- EC5. Subject has acute arterial embolism on either side or suffers from known moderate or greater stenosis at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery
- EC6. Subject has known aneurysm(s) or current limiting dissection at abdominal aorta, ipsilateral iliac artery and ipsilateral lower extremity artery
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who received percutaneous mechanic thrombectomy and iliac vein stenting.
The group in the trial
- Anticoagulant plus antiplatelet therapyTreatment being tested
For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Treatment: Rivaroxaban and Aspirin
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
- Plain-language title
- Rivaroxaban plus aspirin after iliac vein stenting for deep vein thrombosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT04694248, who can take part
- Record updated
- 25 September 2025